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The Journal of Immunology
Complement Evasion Mediated by Enhancement of Captured
Factor H: Implications for Protection of Self-Surfaces from
Complement
Andrew P. Herbert,* Elisavet Makou,* Zhuo A. Chen,† Heather Kerr,*,‡ Anna Richards,‡
Juri Rappsilber,† and Paul N. Barlow*
In an attempt to evade annihilation by the vertebrate complement system, many microbes capture factor H (FH), the key soluble
complement-regulating protein in human plasma. However, FH is normally an active complement suppressor exclusively on self-
surfaces and this selective action of FH is pivotal to self versus non-self discrimination by the complement system. We investigated
whether the bacterially captured FH becomes functionally enhanced and, if so, how this is achieved at a structural level. We found,
using site-directed and truncation mutagenesis, surface plasmon resonance, nuclear magnetic resonance spectroscopy, and cross-
linking and mass spectrometry, that the N-terminal domain of Streptococcus pneumoniae protein PspC (PspCN) not only binds FH
extraordinarily tightly but also holds it in a previously uncharacterized conformation. Functional enhancement arises from
exposure of a C-terminal cryptic second binding site in FH for C3b, the activation-specific fragment of the pivotal complement
component, C3. This conformational change of FH doubles its affinity for C3b and increases 5-fold its ability to accelerate decay of
the binary enzyme (C3bBb) responsible for converting C3 to C3b in an amplification loop. Despite not sharing critical FH-binding
residues, PspCNs from D39 and Tigr4 S. pneumoniae exhibit similar FH-anchoring and enhancing properties. We propose that
these bacterial proteins mimic molecular markers of self-surfaces, providing a compelling hypothesis for how FH prevents
complement-mediated injury to host tissue while lacking efficacy on virtually all other surfaces. In hemolysis assays with
2-aminoethylisothiouronium bromide–treated erythrocytes that recapitulate paroxysmal nocturnal hemoglobinuria, PspCN
enhanced protection of cells by FH, suggesting a new paradigm for therapeutic complement suppression. The Journal of
Immunology, 2015, 195: 4986–4998.
T
he vertebrate complement system is a network of plasma
and cell-surface proteins. Upon activation, these pro-
teins cooperate to selectively tag and eliminate invading
organisms and immune complexes along with products of apoptosis
and oxidative damage (1). Bacterial complement-evasion strate-
gies are targets for novel antibiotics or vaccines, although thera-
peutic suppression of complement activation is desirable in many
diverse clinical contexts (2).
Central to the “alternative” pathway of complement activation
(3) is a positive-feedback loop that amplifies rapidly the protein
C3b (Fig. 1A). In this pathway, a trickle of C3b arises spontane-
ously from low-level proteolysis of the abundant plasma precur-
sor, C3. Amplification may ensue via participation of C3b in the
binary complex, C3bBb. This cleaves (converts) C3 to yield ad-
ditional C3b. Nascent C3b has a transient capability to bond co-
valently, via a thioester-containing domain (TED), to virtually any
nearby surface. Thus, unless complement regulators intercede,
C3b amplification kicks off and all host and foreign surfaces in the
vicinity risk being coated in C3b. C3b is an opsonin and an ini-
tiator of further steps in complement, promoting inflammation and
cytolysis. C3b also arises via other complement-activation path-
ways. Crucially, it is the selective actions of complement regu-
lators that limit C3b amplification on a surface and thus determine
the fates of all plasma-exposed cells and particles.
Factor H (FH) (4–7) is the key soluble regulator of C3b
amplification. It is unique in structure, consisting entirely of 20
complement-control protein modules (CCPs) (8, 9) (Fig. 1B).
Factor H inhibits C3bBb formation by competing with factor B
(FB) (precursor of Bb) for binding to C3b, accelerates irreversible
C3bBb decay by displacing Bb, and is a cofactor for factor I (FI)–
catalyzed C3b cleavage, yielding iC3b that cannot bind FB.
Subsequent iC3b cleavage ultimately yields C3d, equating to the
TED of C3b (Fig. 1A). C3b degradation products, including C3d,
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remain covalently tethered to the surface and augment adaptive
immunity. A critical property of FH is that it regulates C3b
preferentially on self-surface. This underpins self versus non-self
selectivity by the complement system. However, despite decades
of effort, the molecular mechanism for the selective regulatory
action of FH is not fully understood.
The importance of FH is highlighted by links between variations
in its gene, CFH, and diseases (10). Responsible for ∼50% of
the risk of age-related macular degeneration (11–14), one CFH
haplotype encodes a substitution in FH CCP 7 contributing to
recognition by FH of self-surface-markers, including glycosami-
noglycans (GAGs) (15–18) (Fig. 1B). Mutations linked to atypical
hemolytic uremic syndrome (aHUS) cluster in C-terminal CCPs
19 and 20 (19, 20). These modules participate, along with CCP 7,
in self-surface binding via GAGs and sialic acids; CCPs 19 and 20
also interact with the TED of C3b and C3b degradation products,
iC3b and C3d (16). CCPs 1–4 of FH bind C3b (but not iC3b/C3d),
are crucial for FI cofactor and C3bBb decay-accelerating activities
(21), and harbor mutations or single nucleotide polymorphisms
linked to age-related macular degeneration, aHUS, and C3 glomeru-
lonephritis (22, 23). Promising therapeutic complement-suppressing
proteins incorporate CCPs 1–5 (24) or CCPs 1–4 plus CCPs 19 and
20 (25, 26). A construct consisting of CCPs 1–4 flexibly linked to
CCPs 19 and 20 inhibited complement-mediated lysis of erythro-
cytes from paroxysmal nocturnal hemoglobinuria (PNH) patients
lacking key membrane-associated regulators (27) (see below).
As chief soluble complement regulator, FH is a prime target
for microbial hijack (28–30). For instance, choline-binding pro-
tein PspC (SpsA, CbpA, Hic) (Fig. 1C) from the nasopharyngeal
commensal bacterium Streptococcus pneumoniae recruits host-
derived FH from plasma and onto the bacterial surface (31–33).
Invasion of blood by S. pneumoniae can cause pneumonia, menin-
gitis, and septicemia. Serotype invasiveness seems to rely on bacterial
ability to bind FH, although the functional activities of bacteria-bound
FH were not experimentally compared with those of circulating
FH. Differences in levels, or allelic variation, of PspC are likely
responsible for variations in bacterial FH binding (34).
An evolutionary host-pathogen arms race may have helped to
define the enigmatic relationship between the unique 20-CCP
structure of FH and its key property of self-surface selectivity.
Complete reliance on preferential binding by FH, to distinguish
self-surfaces from foreign ones, would be wide open to exploitation
via simple capture on a bacterial surface. We now show that an
N-terminal domain of S. pneumoniae protein PspC (PspCN) not
only binds FH extraordinarily tightly, but is also able to stabilize,
via an allosteric effect, a previously unreported, functionally
enhanced, conformation of FH in which an occluded C-terminal
TED/C3d-binding site is exposed. The ability of FH to bind C3b
is thereby enhanced 2-fold and its C3bBb decay-accelerating
activity is improved 5-fold. This could be an example of a bacterial
protein mimicking molecular markers of self-surfaces.
Materials and Methods
Preparation of proteins
Plasma-derived human complement proteins from Complement Technol-
ogies (Tyler, TX) were used without further purification. Recombinant
human FH, with a wild-type sequence, was produced in recombinant Pichia
pastoris in a fermentor and purified after enzymatic deglycosylation (35).
Expression-optimized DNA encoding the FH(D1119G) mutant was synthe-
sized (GeneArt–Life Technologies) and subcloned into P. pastoris expres-
sion vector pPICZaB. Production of pure recombinant FH (rFH; D1119G)
was performed as described for rFH. A set of rFH module fragments
(Fig. 1B) was prepared from recombinant P. pastoris as described (16).
Synthetic genes encoding the appropriate residues of PspC from D39
S. pneumoniae (see Fig. 1C) or 37–179 from Tigr4 S. pneumoniae were
optimized for Escherichia coli (GeneArt–Life Technologies) and cloned
into E. coli vector pE-SumoProKan (LifeSensors, Malvern, PA) then expressed
in BL21 (DE3) E. coli. Protein production was induced by addition of iso-
propyl b-D-1-thiogalactopyranoside. The resultant hexa-His-SUMO–tagged
proteins (see Fig. 1C) were captured on a HisTrap column (GE Healthcare)
and eluted with a gradient to 0.5 M imidazole. They were further purified
by size-exclusion chromatography (HiPrep Superdex 75 column, GE Health-
care) in PBS. For most experiments, the catalytic domain from SUMO-specific
protease, ULP1, was used to cleave the hexa-His-SUMO tag from fusion
constructs and the tag removed on a HisTrap column. The cleaved material
was purified by size-exclusion chromatography. Homogeneity was con-
firmed by SDS-PAGE and mass spectrometry (MS) (data not shown).
Measurement of FH binding to PspCN by surface plasmon
resonance
Surface plasmon resonance (SPR) experiments were performed at 25˚C on a
Biacore T200 instrument (GE Healthcare) using 10 mM HEPES, 150 mM
NaCl, 0.05% (v/v) surfactant P20 (pH 7.4) supplemented with 50 mM
FIGURE 1. Proteins used in this study. (A) The alternative pathway pro-
duces, spontaneously, low levels of C3b from inert C3. Nascent C3b can
attach to nearby surfaces via its TED. C3b also binds FB, forming C3bB.
Factor D (FD) cleaves the FB portion of C3bB, yielding C3bBb. C3bBb
converts C3 to C3b (+ C3a), establishing a positive-feedback loop for C3b
production. On a self-surface, FH competes with FB for C3b binding and
accelerates decay of C3bBb. C3b can be degraded to iC3b by FI with FH
as cofactor and then via C3dg (+ C3c) to C3d, equating to the TED of C3b.
(B) Ovals represent CCPs 1–20 in FH; locations of N-glycans are indicated
by rectangles. Horizontal lines above the ovals designate CCPs involved in
binding C3b (ovals with thicker outline), self-surface markers (pale shading),
and C3d (pale shading plus thicker outline); dashed lines indicate constitu-
tively occluded binding sites. (C) N-terminally His6-tagged SUMO fusions (s)
with sequences from the N-terminal domain of D39 PspC (residue
numbering includes signaling sequence) were created. The sPspCN37–140
or the product (PspCN) following cleavage of and removal of the fusion
partner was used for most experiments.
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EDTA. Routinely, Ni2+ (typically ∼50 response units [RU]) and subse-
quently the PspC-derived proteins were immobilized on a Biacore NTA
chip via N-terminal His6-SUMO tags (typically ∼150 RU). Solutions of
plasma-derived FH, rFH, or rFH fragments were flowed over the chip
(180 s, 100 ml/min) followed by a dissociation phase of 1500 s. Because
effectively irreversible binding of FH occurred, the chip was regenerated
between measurements by two 30-s injections of 350 mM EDTA in 1 M
NaCl, then 50 mM NaOH, followed by 0.5% (w/v) SDS. Data were ana-
lyzed using the Biacore evaluation software and a 1:1 binding model. No
refractive index correction or mass transport correction was applied; the
drifting baseline was corrected by subtracting the signal obtained from an
injection of 0 concentration of analyte.
We also observed effectively irreversible binding of FH to PspCN (after
cleavage of the His6-SUMO tag) amine coupled to a Biacore CM5 chip,
and to nontagged PspCN, with a C-terminal cysteine, thiol coupled to a
Biacore C1 chip (data not shown). Use of the Ni-NTA chip, however,
minimized the risks, associated with amine coupling, of heterogeneous
protein deposition and masking of ligand-recognition sites. It also facili-
tated regeneration of the chip surface. Its disadvantages were slow ongoing
leaching of His6-tagged SUMO fusion of D39 PspCN (sPspCN) from the
surface, and the the potential for FH and some FH fragments to bind di-
rectly to divalent cations, including Ni2+ (36). Indeed, we observed weak
binding of FH (see Supplemental Fig. 1) and moderate binding of FH 6–8
to the Ni-NTA chip surface. These difficulties were circumvented by
background subtraction.
Measurement of FH and FH:PspCN binding to C3b and C3d
by SPR
In these experiments C3b (typically ∼250 RU) or C3d (typically ∼70 RU)
was amine coupled to adjacent flow cells of a Biacore C1 chip (another
flow cell was used for background subtraction). Solutions of FH (pre-
incubated with or without a 2-fold molar excess of PspCN) were injected
(90 s, 30 ml/min) over the chip, followed by a 400-s dissociation phase.
The sensor chip was regenerated by two injections of 1 M NaCl. Data were
analyzed using the Biacore evaluation software and a 1:1 binding model.
C3bBb decay-accelerating assay
Decay-accelerating activity was measured in an SPR-based assay as de-
scribed (37). In brief, ∼500 RU C3b was amine coupled to a Biacore CM5
chip, then C3 convertase (C3bBb) was assembled on the chip by a 120-s
10 ml/min injection of 500 nM FB plus 50 nM complement factor
D. Formation of C3 convertase (to ∼150 RU) was monitored, then an
initial dissociation phase (200 s) allowed observation of intrinsic con-
vertase decay (Bb loss). Subsequently, FH or FH:PspCN was injected
(10 ml/min for 120 s), followed by a further dissociation phase. The chip
FIGURE 2. FH binds irreversibly to (D39)PspCN.
(A) A 2-fold dilution series, from 8 to 0.25 nM, of
plasma-purified human FH was flowed (in dupli-
cate) over D39 His6-Sumo-PspCN immobilized
(to Ni-NTA) in an SPR experiment (see also
Supplemental Fig. 1). (B) The experiments shown in
(A) were repeated with recombinant wild-type FH
(left) or rFH(D1119G) (right). In (A) and (B), solid
black lines indicate fitted curves. (C) A 2-fold di-
lution series from 40 to 2.5 nM of FH was flowed
(in duplicate) over recombinant sPspCN truncations
(as indicated using residue numbers, see Fig. 1C)
immobilized on Ni-NTA. Residues 61–140 repre-
sent the minimum region of D39 PspC shown
in the present study to bind tightly to FH, but
(D39)PspC37–140 (i.e., PspCN) was used for fur-
ther experiments owing to its greater stability.
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was regenerated between cycles by a 30-s injection of 0.2 mM FH and two
30-s injections of 1 M NaCl.
FI cofactor assay
The activity of FH as a cofactor for FI-catalyzed C3b cleavage was
measured by detection of its initial a9-chain proteolytic products (63 and
39 kDa) following SDS-PAGE. The non-cleaved b-chain served as an
internal control. The initial 16-ml reaction mixture contained 1.7 mM C3b,
14 nM FI, and a range of concentrations (80, 40, 20, 10 nM) of FH, either
alone or with a 10-fold molar excess of PspCN. The reaction mixture was
incubated for 30 min (37˚C), then stopped by addition of SDS-PAGE
loading buffer. The mixture was boiled for 300 s and subjected to PAGE.
Hemolytic assay
Sheep and rabbit whole blood was from TCS Biosciences (Buckingham,
U.K.). FH-depleted normal human serum (FHDNHS) was from Comple-
ment Technology. Hemolysis assays were performed in 96-well plates as
described (38), except HEPES replaced veronal buffer. Erythrocytes were
washed thrice with 20 mM HEPES, 145 mM NaCl, 10 mM EDTA, and
0.1% (w/v) gelatin (porcine skin, Fluka) (pH 7.3) (buffer H1), and a further
three times with 20 mM HEPES, 145 mM NaCl, 100 mM EDTA, and 0.1%
(w/v) gelatin (pH 7.3) (buffer H2). Erythrocytes were used at a concen-
tration that gave a final absorbance at 412 nm of 1.0 (rabbit) or 1.2 (sheep)
when lysed completely in water. FHDNHS was reconstituted with FH to
2 mM and then combined, on ice, and made up to the final concentrations
indicated, with erythrocytes and buffer H2 yielding a 45 ml final volume.
Lysis was initiated by addition of 5 ml 50 mM Mg2+, 50 mM ethylene
glycol tetra-acetic acid (pH 7.3). The reaction was incubated (37˚C,
30 min) and then quenched with 200 ml buffer H1. Nonlysed cells and cell
debris were pelleted (15003 g, 10 min, 4˚C), then 100 ml supernatant was
taken for A412 measurement.
Protection against hemolysis of “PNH-like” erythrocyte
Human erythrocytes lacking GPI-linked proteins (PNH-like) were prepared
according to a modified version of the method of Ezzell et al. (39). Whole
human blood was obtained by phlebotomy and stored in Alsever’s solution
(4˚C). Human blood samples were obtained for this study exclusively from
healthy adult volunteers who provided written informed consent, in ac-
cordance with the Research Ethics Framework of the College of Science
and Engineering of the University of Edinburgh and guidance from the
University of Edinburgh’s Research Ethics Committee. Cells were washed
three times with wash buffer (20 mM HEPES, 145 mM NaCl, 10 mM
EDTA, 0.1% [w/v] gelatin [pH 7.3]) and then resuspended in PBS. After
each wash step the top 10% of the cell pellet was aspirated to remove the
white cell–containing buffy coat. For removal of decay-accelerating factor
and other GPI-linked proteins, a 1-ml aliquot of packed cells was added
to an 8% (w/v) solution of 2-aminoethylisothiouronium bromide (AET,
Sigma-Aldrich) solution that had been titrated to pH 8.0 with HCl. The
cell suspension was incubated for 9 min (37˚C) with constant agitation,
after which the resultant PNH-like cells were washed three times with
wash buffer containing no EDTA.
For hemolysis assays, the PNH-like cells were washed with 20 mM
HEPES, 145mMNaCl, 0.1% (w/v) gelatin (pH 6.4) and then incubated (37˚C)
with acidified NHS, 5 mM magnesium EGTA, and the appropriate concen-
tration of either plasma-purified FH or purified rPspCN, in a total reaction
volume of 50 ml. After 30 min the reaction was quenched by the addition of
200 ml ice-cold buffer (20 mM HEPES, 145 mM NaCl, 10 mM EDTA, 0.1%
[w/v] gelatin [pH 7.3]). The cells and cell debris were removed by centri-
fugation (30003 g, 10 min, 4˚C), after which a 100-ml aliquot was removed
and its absorbance at 412 nm recorded.
Assessment of oligomeric status
For determination of oligomeric status, samples (4.6 mM in PBS) of FH,
PspCN, or of a 1:1 complex of these proteins were characterized by size-
exclusion chromatography–multiple-angle light scattering. Following
passage through a Superose12 10/300 GL column (GE Healthcare) operating
at 0.4 ml min21, the eluate was subjected to measurements of absorbance,
refractive index, and light scattering using a Dawn Heleos II detector (Wyatt
Technology). Data were analyzed by ASTRA software. Samples as above
were also subjected to analysis using a Beckman XL-A ultracentrifuge with
an An-50 Ti eight-hole rotor (Beckman Instruments, Fullerton, CA). Velocity
sedimentation analysis was performed at 40,000 rpm (25˚C). The sedi-
menting boundary was monitored every 90 s until completion. Data were
processed using sedimentation coefficient distributions analysis in SEDFIT
(40).
Nuclear magnetic resonance spectroscopy
Spectra were acquired on an Avance II 800 MHz spectrometer (Bruker)
using a 5-mm TCI CryoProbe (Bruker). Data were processed using TopSpin
3.1 (Bruker) and analyzed using CcpNmr analysis software (41). Samples
of 15N-FH 8–9 and 15N-PspCN were used to optimize conditions by
varying NaCl from 0 to 150 mM (pH from 4 to 6.5) and temperature from
15 to 70˚C. Subsequently, 40 mM 15N-FH 8–9 in 20 mM potassium
phosphate (pH 6.2) was used to record a 1H,15N HSQC spectrum at 310 K,
then PspCN was added to 100 mM and the spectrum was rerecorded.
Separately, 30 mM 15N-PspCN in 20 mM potassium phosphate (pH 6.0)
was used to record a 1H,15N HSQC spectrum at 298 K, then FH 8–9 was
added to 40 mM and the spectrum was rerecorded.
Cross-linking and MS/MS
Samples (20 mg) of plasma-purified FH or FH plus PspCN (1:1.15 FH/
PspCN molar ratio) were cross-linked with bis(sulfosuccinimidyl) suberate
(BS3) using 1:0.5 or 1:4 mass ratios of protein to BS3, and an hFH con-
centration of 0.56 mg/ml in the reaction mixtures. Products of cross-linking
were resolved by SDS-PAGE on a NuPAGE 4–12% Bis-Tris gel (Invitrogen),
with MOPS running buffer, then stained with InstantBlue (Expedeon). Five
FIGURE 3. (D39)PspCN binds FH 8–9 but addi-
tional CCPs are essential for irreversible binding.
D39 sPspCN was immobilized as in Fig. 2A. (A)
Comparison of binding curves obtained for 8 nM FH
as well as 50 nM FH 8–9, FH 8–15, FH 10–15 (near
baseline), or FH 19–20 (just above baseline). (B)
Expanded segment of the sensorgram in (A) high-
lighting small responses for FH 19–20 and FH 10–15
(KD values could not be estimated). (C) An FH 8–9
concentration series was flowed over immobilized
D39 sPspCN to allow estimates (equilibrium method)
of KD of 30 nM. Another series for FH 8–15 (not
shown) yielded a KD of 1 nM.
The Journal of Immunology 4989
 at Edinburgh U
niversity on D
ecem
ber 17, 2015
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
excised bands corresponding to cross-linked products (see Fig. 5A) were
subjected to in-gel tryptic digestion as described (42). For each sample, cross-
linked peptides were fractionated using an SCX-StageTip (43); non–cross-
linked peptides generally elute at 60 mM ammonium acetate whereas
cross-linked peptides are enriched in the 500 mM ammonium acetate frac-
tions. High-salt fractions were analyzed by liquid chromatography–MS/MS
using a Q Exactive instrument (Thermo Fisher Scientific). Peptides were
separated on an analytical column containing ReproSil-Pur C18-AQ 3 mm
(Dr. Maisch, Ammerbuch-Entringen, Germany) into a PicoTip emitter
(New Objective, Woburn, MA). For elution, a linear gradient was applied
from 1.6 to 32% (v/v) acetonitrile in water during 109 min, followed by
a rapid increase to 76% (v/v) acetonitrile. Mass spectrometric acquisitions
were conducted in a data-dependent setup: following each MS scan, the 10
most intense ions were isolated and fragmented by higher energy C-trap
dissociation. Both MS and MS/MS spectra were recorded in the Orbitrap
analyzer with 70,000 resolution for MS scans and 35.000 for MS/MS
scans. “Dynamic exclusion” was set to 60 s; “repeat count” was set to 1.
Fifty cross-linked peptides were identified using in-house software
(Supplemental Table I). Label-free quantitation was performed at linkage
level as follows. For each unique linkage, mass spectrometric chromato-
graphic signal intensities of all corresponding cross-linked peptides were
retrieved using Pinpoint software (Thermo Fisher Scientific) and summed.
To ensure unbiased comparisons across samples, signal intensities of in-
dividual linkage pairs were normalized using the summed signal intensity
of 23 cross-linked (and 29 non–cross-linked) FH peptides observed in all
five samples. The intensity variation of a cross-link across the five samples
was thereby reflected in its relative intensity within each sample, calcu-
lated as the logarithm to base 5 of the quotient of the observed intensity
and the average intensity, of this cross-link, in five samples. Relative
abundances of each cross-linked peptide among the three samples (s1, s2,
and s4, as explained in Results) that did not contain dimeric FH were
calculated. Then, for description and presentation purposes, cross-links
were categorized in the following way: enriched in s1 (.65% in s1);
enriched in s1 and s2 (.40% in each of s1 and s2); enriched in s2 and s4
(.40% in each of s2 and s4); enriched in s2 (.65% in s2); enriched in s4
(.65% in s4); and all the rest (present approximately equally in all three of
s1, s2, and s4) (see Supplemental Table I).
The cross-linking and MS (CLMS) experiment was repeated and pro-
duced essentially the same results (not shown).
Results
The N-terminal domain of D39 PspCN binds effectively
irreversibly to FH
The FH-binding site of the S. pneumoniae protein, PspC (Fig. 1C),
lies within its variable N-terminal region (44–46). To explore the
boundaries of this binding site and measure the affinity of the in-
teraction, we produced His6-SUMO–tagged proteins corresponding
to N-terminal regions of PspC from the virulent S. pneumoniae
strain, D39. We used SPR to monitor capture of FH flowed over
these proteins immobilized on a Ni2+-bearing sensor chip (Fig. 2A).
Binding of FH to D39 PspC residues 37–140 was remarkably tight
with a barely detectable off-rate (,0.2% over 30 min), equating to
a pM KD. Recombinant wild-type and D1119G mutant (see below)
versions of FH bound with equally strong affinities (Fig. 2B). The
smallest tested D39 PspC fragment that still bound tightly to FH
contained residues 61–140 (Fig. 2C). Smaller fragments were, how-
ever, less soluble after cleavage from His6-SUMO, so we used D39
PspCN 37–140 [henceforth (D39)PspCN] for further experiments.
FIGURE 4. NMR-based study of FH 8-9:PspCN complex. 1H,15H(NMR) spectra for (A) free D39 15N-PspCN, (B) D39 15N-PspCN bound to FH 8–9, (C)
free 15N-FH 8–9, (D) 15N-FH 8–9 bound to (D39)PspCN. Differences between (A) and (B) suggest D39(PspCN) adopts a more compactly folded structure
upon binding FH 8–9. Many chemical shift differences between (C) and (D) suggest extensive contacts between FH 8–9 and (D39)PspCN. For higher
resolution and overlaid spectra (see Supplemental Fig. 2).
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FIGURE 5. Architecture and oligomeric status of FH:PspCN complexes. (A) Cross-linked products were resolved by SDS-PAGE. Lane 1, molecular
mass markers; lanes 2 and 3, cross-linker (BS3) mixed with FH (0.5:1 BS3/protein molar ratio); lanes 5 and 6, as lanes 2 and 3 but 4:1 BS3/protein molar
ratio; lanes 8 and 9, BS3 mixed with FH:(D39)PspCN complex (4:1 BS3/protein complex molar ratio). Coomassie-stained bands (labeled s1–s5) were cut
out for MS/MS analysis (Supplemental Table I): s1 and s2 correspond to distinct monomeric species with different migration rates, s3 corresponds to
a cross-linked dimer, and s4 and s5 correspond to a cross-linked FH monomer and dimer, respectively, in complex with (D39)PspCN. (B) In cartoons of FH,
numbered ovals indicate CCPs and dotted connectors represent cross-linked peptide pairs detected by MS/MS in analysis of SDS-PAGE bands corre-
sponding to monomeric FH (s1 and s2) or the 1:1 FH:PspCN complex s4. Connectors are black when they represent cross-links that are observed equally in
all three bands (s1, s2, and s4) or colored when they are selectively enriched in one or two bands (see key, Materials and Methods and Supplemental
Table I). (C) Size-exclusion chromatograms and multiple-angle light scattering–derived molecular masses for FH and FH:(D39)PspCN complex. The 155-
kDa value for FH matches the calculated monomeric molecular mass. Material in the main FH:PspCN peak had a mean estimated molecular mass of
172 kDa, close to that expected for 1:1 (167 kDa). The FH:PspCN peak has a trailing shoulder attributable to nonspecific association with resin. A minor
peak (molecular mass of 189 kDa) could represent some 1:2 or 1:3 FH:PspCN complexes, but there was no evidence of complexes containing
two molecules of FH ($310 kDa). (D) Analytical ultracentrifugation of free FH showed a single species; FH:(D39)PspCN also behaved in analytical
ultracentrifugation as a single species with a higher Svedberg value than free FH.
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(D39)PspCN binds directly to central CCPs, but full-length FH
is needed for pM binding
PspC from various strains of S. pneumoniae was reported to bind
to diverse segments of FH, for example CCPs 8–11, CCPs 13–15,
and CCPs 19 and 20 (44, 45, 47, 48). To further map the FH-
binding site of D39 PspCN, we flowed, in an SPR experiment, our
existing library of rFH fragments (16) (Fig. 1B) over immobilized
(via His6-SUMO) (D39)PspCN (Fig. 3). On the one hand, binding
of (D39)PspCN to the following fragments was undetectable or
negligible: FH 1–4, FH 6–8, FH 10–11, FH 10–15, and FH 19–20.
On the other hand, (D39)PspCN bound well to FH 8–9 (KD = 306
2 nM) and bound even better to FH 8–15 (KD = 1 6 0.1 nM).
None of the fragments bound to (D39)PspCN in the effectively
irreversible manner observed for intact FH.
To further address the participation of CCPs 8 and 9 of FH in
PspCN binding, 1H,15N heteronuclear single-quantum coherence
nuclear magnetic resonance (NMR) spectra of 15N-PspCN were
recorded with and without FH 8–9 (Fig. 4A, 4B, Supplemental
Fig. 2). The spectrum of (D39)PspCN suggests a molten globule
as was supported by its binding of anilino-1-naphthalenesulfonic
acid (data not shown). Following complex formation with FH 8–9,
bound PspCN yielded a spectrum containing well dispersed and
resolved cross peaks, reflecting transition to a folded conformation
upon complex formation. In other experiments, spectra of 15N-FH
8–9 were recorded with or without unlabeled PspCN (Fig. 4C,
4D). Judging from the uniform appearance of the well-dispersed
cross peaks, both modules appeared to be compactly folded with
any mobility restricted to loops and turns. Fig. 4D reveals nu-
merous chemical-shift perturbations, reflecting plentiful contacts
with PspCN in CCPs 8 and 9, as may also be judged from the
overlaid spectra in Supplemental Fig. 2.
CLMS was used to provide additional and orthogonal evidence
for which FH regions contact (D39)PspCN. The reagent BS3,
which cross-links pairs of primary amines within 11.4 A˚ of each
other, was added to mixtures of FH and PspCN. Products resolved
by SDS-PAGE (Fig. 5A) were excised from the gel and trypsinized,
and then MS/MS was used to identify cross-linked peptides
(Supplemental Table I). Within the product of cross-linking cor-
responding to a 1:1 PspCN:FH complex (band s4, Fig. 5A), just
five cross-links were identified between PspCN and FH, one in-
volving CCP 9 and four involving CCP 10 (Fig. 5B).
All these data suggest that CCP 9 of FH is essential for binding
(D39)PspCN. Immediately adjacent CCPs likely also contact (D39)
PspCN but, in the absence of CCP 9, for example, in the contexts of
FH 6–8 and FH 10–15, their affinity for (D39)PspCN was not
measurable by SPR. It is also possible that CCP 10 does not
contact PspCN directly but contributes to affinity by stabilizing
adjacent loops in CCP 9. Direct engagement with at most three
∼6.5-kDa FH modules (CCPs 8–10) is consistent with the pre-
dicted size and hence available surface area of compactly folded
12-kDa (D39)PspCN. The extraordinarily tightness of the PspCN
complex with full-length FH is noteworthy. It arises from an
FIGURE 6. Binding properties of wild-type
(plasma-derived) FH with and without D39 PspCN.
(A and B) Demonstration by SPR that FH (A) has
lower affinity than does the FH:(D39)PspCN com-
plex (B) for immobilized C3b (amine coupled on
a C1 chip). (C and D) The lower affinity of FH for
C3b may arise from FH (C) having a very sub-
stantially lower affinity than the FH:(D39)PspCN
complex (D) for immobilized C3d amine coupled to
a different channel of the same C1 chip as used in
(A) and (B).
Table I. Dissociation constants for FH binding to immobilized C3b and C3d measured by SPR
Analyte
C3b C3d
KD (mM) SE (KD) x
2 (RU2) Rmax (RU) KD (mM) SE (KD) x
2 (RU2) Rmax (RU)
FH 0.49 0.024 0.14 76 ND — — —
FH + PspCN 0.16 0.059 0.5 134 2.3 0.16 0.4 102
FH + Tigr437–179 0.28 0.030 1.1 60 1.2 0.10 0.1 70
rFH 0.60 0.053 3.8 147 ND — — —
rFH + PspCN 0.28 0.060 16.0 113 2.2 0.37 0.8 100
FH(D1119G) 0.54 0.093 9.4 63 ND — — —
FH(D1119G) + PspCN 0.32 0.042 12.6 79 ND — — —
Rmax, maximum response.
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extremely slow off-rate, attained by full-length FH but not recapit-
ulated by FH fragments. (D39)PspCN is likely trapped within the
complex by a very stable PspCN-induced global rearrangement of
CCPs. To explore further, we recorded intramolecular CLMS data
for FH before and after (D39)PspCN addition.
Analysis of FH architecture by CLMS
SDS-PAGE of FH (with no cross-linker) yielded a band com-
mensurate with its 155-kDa molecular mass (data not shown).
Inclusion of the bifunctional cross-linker BS3 yielded bands s1 and
s2 (in Fig. 5A) that are consistent with a pair of differently mi-
grating populations of conformers of cross-linked monomeric FH,
as well as bands corresponding to cross-linked FH dimer (s3) and
higher oligomers. Band s2 contained more head-to-tail cross-links
(Fig. 5B, Supplemental Table I) than did band s1. The detection of
a cross-link between side-chains in the same molecule is evidence
that the two residues are proximal for at least some of the time or
in at least a portion of conformers, although this cannot be
quantified. The absence of a cross-link cannot, however, be used
as evidence for lack of proximity because there are numerous
reasons why a cross-link between two bridgeable amino groups
(,11.4 A˚ apart in this case) might not form or might not be
identified. Nonetheless, the simplest explanation for the difference
between the patterns of cross-links in s1 and s2 is the presence of
more bent-back FH conformations in s2 than in s1, reflecting the
coexistence of both extended conformations and more compact
ones in solution. The identification of multiple cross-links from
CCP 20 to CCP 4, CCP5, and CCP 7 in s2 implies flexibility in the
C terminus.
After addition of D39 PspCN to FH and incubation with the
cross-linker, a single monomer-candidate band (s4) replaced s1
and s2, and a dimer-candidate band (s5) was enhanced (Fig. 5A).
Both s4 and s5 contained PspCN cross-linked to FH CCPs 9 and
10 (as noted above). Comparison of the monomeric FH-containing
bands s1, s2, and s4 (Supplemental Table I) revealed 15 differ-
ences between cross-links in the presence of PspCN (s4) com-
pared with the absence of PspCN (s1 and s2), that is, cross-links
that are selectively enriched in either or both of s1 and s2, or
enriched in s4. Of these 15 cross-linked peptides, 13 involve CCPs
3–8 or CCPs 18–20 and 11 out of these 13 involve either or both
of CCP 7 and CCP 20; 3 of the 15 connect CCPs 7 and 8 (Fig. 5B,
Supplemental Table I). Note that the s2 (no PspCN) cross-link
between CCP 7 and CCP 20 involves different residues to the
two s4 (plus PspCN) cross-links between CCP 7 and CCP 20.
Although cross-linking data should be interpreted cautiously, these
differences strongly suggest that FH undergoes a change in con-
formational preferences upon binding PspCN. Moreover, the
identity of the lost or gained cross-links implies that the allosteric
effect of PspCN involves differences in the juxtaposition of N- (CCPs
1–7) and C-terminal (CCPs 18–20) regions of the FH molecule.
The new conformational preferences of FH induced by PspCN
are likely stabilized by both intermolecular and intermodular,
intramolecular contacts. These could account for the near-zero
dissociation rate for this complex. PspCN-stabilized FH con-
formers may have nascent self-association sites, accounting for the
increased intensity of the dimer band s5. Nonetheless, analysis
by size-exclusion chromatography–multiple-angle light scattering
(Fig. 5C) and analytical ultracentrifugation (Fig. 5D) failed to
detect FH dimerization, in the absence of BS3, either before or
after PspCN addition. Thus, any self-association of PspCN:FH is
weak.
In short, although NMR shows that PspCN folds on binding FH,
differences in cross-linking yields suggest that the conformational
landscape of FH is modulated by PspCN. N- and C-terminal
regions, corresponding to the principal C3b-binding segments of
FH (see Fig. 1B), account for most of the differences in identified
FIGURE 7. Functional properties of wild-type and mutant FH with and without D39 PspCN. (A) Formation of C3bBb from C3b, FB, and FD on the chip
surface (see Fig. 1A) and subsequent loss of Bb, monitored by SPR. Curves are color coded (see key). Note that 100 nM PspCN alone has no activity; 5 nM
FH:(D39)PspCN complex accelerated decay better than did 10 nM FH alone. (B) Incrementally increasing FH from 10 to 80 nM correlates with greater
fluid-phase FI cofactor activity, judging by stronger bands representing the C3b a9-chain cleavage products at 39 and 63 kDa, and loss of intensity of the
band corresponding to intact a9-chain. PspCN lacks intrinsic cofactor activity whereas binding of PspCN to FH does not enhance its activity. (C) In
a parallel experiment to that of (A), 5 nM FH(D1119G) and 5 nM wild-type FH have similar DAAs but (D39)PspCN enhances the activity of wild-type FH
more than it enhances the activity of FH(D1119G).
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cross-links. We therefore explored the functional consequences for
FH of being anchored to (D39)PspCN.
New binding site for TED/C3d exposed by (D39)PspCN
binding
Human C3b and C3d (corresponding to the TED of C3b) were
amine coupled to an SPR chip. Having checked that (D39)PspCN
did not bind to immobilized C3b or C3d (data not shown), the
affinities of FH and the (D39)PspCN:FH complex for these C3
fragments were compared (Fig. 6). The KD for FH:C3b, 490 nM
(see Table I), matched literature values. Crucially, (D3)PspCN:FH
bound tighter to C3b (KD = 160 nM) than did FH alone (Fig. 6A,
6B). This enhancement proved to be reproducible in further mea-
surements; in a total of 10 entirely independent measurements, the
ratio of KD values for FH versus FH-PspCN was 2.04 6 0.56.
Alone, FH bound very poorly to C3d immobilized on the SPR
chip (Fig. 6C, Table I). Although similar data may be found in the
literature (25, 26, 49), this observation is remarkable given that the
two-module C-terminal FH fragment, FH 19–20, binds to C3d
with KD of ∼2 mM (16, 49). Strikingly, the D39 PspCN:FH
complex bound many times better to C3d than did FH alone
(Fig. 6C, 6D, Table I). Indeed, the KD of 2 mM for this interaction
is reminiscent of that for the FH 19–20:C3d interaction.
In sum, the C3d-binding site (that is presumably also a C3b/
TED-binding site) within the C-terminal CCPs of FH is largely
inaccessible within full-length FH operating on a SPR chip.
Our data show that binding of (D39)PspCN to FH exposes this
C-terminal C3d/TED-binding site by remodeling FH. This allows
the PspCN:FH complex (unlike FH alone) to bind well to C3d, and
to bind C3b more tightly (presumably using two sites) than FH
alone (using one site). We speculated that (D39)PspCN induces an
“enhanced” form of FH similar to that induced by molecular
markers on self-surfaces requiring protection from complement
activation.
PspCN enhances the potential of FH to regulate complement
If capture by PspCN exposes a C3d/TED-binding site in FH, does it
modulate the principal role of FH, that is, inhibition of the C3b-
amplification loop? We measured effects of (D39)PspCN on the
convertase decay-accelerating activity (DAA) of FH (Fig. 1A). To
do this, we monitored C3bBb formation on the SPR chip followed
by its dissociation into C3b and Bb, before and after addition of
FH or (D39)PspCN:FH (Fig. 7A). Predictably, 5 and 10 nM FH
dose-dependently accelerated C3bBb decay; 100 nM (D39)PspCN
alone had no effect. Strikingly, 5 nM (D39)PspCN:FH was at least
twice as active as 10 nM FH (alone). We next checked whether
(D39)PspCN:FH has enhanced cofactor activity (Fig. 1A) by in-
cubating C3b and FI with either FH or (D39)PspC:FH. No dif-
ference was detected (Fig. 7B). That PspCN enhances DAA and
affinity for C3b of FH, but does not increase cofactor activity, is
readily explicable. For example, by increasing binding of FH to
iC3b, PspCN could impede product (iC3b) release (from the FH:
FI:iC3b complex) and slow down turnover. Another explanation is
that FI recruitment to C3b:FH (perhaps unaffected by PspCN),
rather than FH binding to C3b, limits efficacy as cofactor.
PspC from S. pneumoniae strain Tigr4 has similar properties
to (D39)PspC
To test whether these properties of FH capture and enhancement
were shared with PspC proteins from other strains of S. pneumoniae,
we produced the N-terminal domain (residues 37–179) of PspC
from the Tigr4 strain of S. pneumoniae, (Tigr4)PspC37–179, that
shares 50% sequence similarity with (D39)PspCN (Fig. 8A).
FH bound equally tightly to both of these proteins (Fig. 8B).
Moreover, the (Tigr)PspC37–179:FH complex had similar proper-
ties to those of (D39)PspCN:FH in terms of enhanced C3b and
C3d binding (Fig. 8D). Finally (Tigr4)PspC37–179 stimulated the
decay-accelerating activity of FH in the same way as did (D39)
PspCN (Fig. 8C).
(D39)PspCN reveals cryptic effects of disease-linked mutation
The results so far imply that only the N-terminal C3b-binding site
of FH engages with C3b on a foreign surface such as an SPR
FIGURE 8. (Tigr4)PspC37–179 shares FH binding and activating prop-
erties with (D39)PspCN. (A) Pairwise (BLAST-P) alignment of N-terminal
sequences from D39 and Tigr4 PspC. The sequence of (D39)PspCN (i.e.,
residues 37–140) is compared with that of (Tigr)PspC37–179. The segment
of Tigr4 PspCN (residues 68–140) used in a recent crystal structure (48) of
a complex with FH CCP 9 (PDB_ID = 4k12) is shaded in gray (boxes
indicate a-helices); yellow and blue highlighting of residues summarizes
information from truncation mutants in Fig. 2C. Intermolecular interface
residues are indicated (red signifies .60% buried) as “X” or “h” (when
H-bonded) or “H” if H-bonded and in salt bridge); *, key interface residue
that is not conserved (analyzed using PISA) (54). (B) In this SPR-based
experiment, a 2-fold dilution series of FH solution from 16 to 0.25 nM was
flowed over immobilized (Tigr4)PspC37–179, suggesting that binding is
irreversible. (C) A complex of (Tigr4)PspC37–179 and FH is more effective
than FH alone at accelerating decay of C3bBb, but not as effective in this
respect as (D39)PspCN:FH. In these experiments, 20 nM FH was used. (D)
(Tigr4)PspCN enhances FH binding to C3b and C3d. In measurements
that were analogous to those of Fig. 6, solutions of either FH (left), or
FH:(Tigr4)PspCN37–179 (right) (at FH 2-fold dilutions from 1000 to 31 nM
in both cases) were flowed over C3b or C3d amine coupled to the SPR
chip. Derived KD values are reported in Table I.
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chip. Its C-terminal C3b(TED)-binding site, we suggest, remains
occluded in the absence of PspCN (or molecular markers of a self-
surface). To test this, we produced rFH(D1119G). This aHUS-
linked substitution has not been extensively characterized in the
context of pure full-length FH. When introduced into the fragment
FH 19–20, however, D1119G markedly reduced both C3d and C3b
binding. Moreover, within a crystal structure of the FH 19–20:C3d
complex, Asp1119 occupies a key position at the intermolecular
interface (49). Although FH(D1119G) has a defective C-terminal
C3b(TED)-binding site, we reasoned this should not impact on
SPR-based measurements of binding to immobilized C3b. Indeed,
we found that full-length FH(D1119G) binds to amine-coupled
C3b just as tightly as does full-length wild-type FH (Fig. 9A,
Table I). Thus, we conclude that the N terminus of FH dominates
its interactions with C3b on a foreign or non-self surface (where
its regulatory activity is not generally desirable). As expected,
FH(D1119G) still bound irreversibly to PspCN (Fig. 2B) but had
no measurable affinity for C3d (Fig. 9C).
We measured binding of the (D39)PspCN:FH(D1119G) com-
plex to C3b and C3d (Fig. 9C, 9D). In contrast to wild-type
FIGURE 9. Binding properties of FH(D1119G) with
and without (D39)PspCN. (A) According to SPR, FH
(D1119G) binds to immobilized C3b with a similar KD
value to that of wild-type FH. (B) Importantly, there is
little enhancement of C3b binding when FH(D1119G)
is complexed with (D39)PspCN. Neither (C) FH(D1119G)
alone nor (D) FH(D1119G):PspCN bind well to C3d.
Insets, Plots to estimate KDs.
FIGURE 10. Cell-based assays. (A) Near-complete human complement-mediated lysis (after 30 min) of rabbit erythrocytes, measured by A412 of the
released hemoglobin at 40% (v/v) FHDNHS. Neither FH, nor FH(D1119G), nor 1:1 FH+FH(D1119G) protected rabbit erythrocytes significantly.
(D39)PspCN:FH(wild-type), but not (D39)PspCN:FH(D1119G), affords some, although incomplete, protection. (B) As expected, FH prevents human com-
plement-mediated hemolysis of (human-like) sheep erythrocytes irrespective of (D39)PspCN, whereas FH(D1119G) provides less protection than does
wild-type FH. Protection of sheep erythrocytes by the 1:1 mixture of FH(wild-type) plus FH(D1119G), recapitulating heterozygosity, is enhanced by
PspCN. (C and D) (D39)PspCN boosts ability of FH in serum to prevent hemolysis of PNH-like human erythrocytes (treated with AET to deprive them of
decay-accelerating factor). These AET-treated cells are susceptible to acidified serum lysis in a similar way to erythrocytes from PNH patients. (C) Adding
increasing concentrations of FH inhibits lysis of the PNH-like erythrocytes. (D) Adding increasing concentrations of (D39)PspCN inhibits lysis of the PNH-
like erythrocytes with an IC50 of 28 nM.
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FH (but in line with our model), the negligible affinity of
FH(D1119G) for C3d is only enhanced slightly by (D39)PspCN
(no KD could be calculated in either case). The enhancement by
PspCN of FH(D1119G) binding to C3b (KD values of 0.33 6 0.04
mM in the presence of PspCN versus 0.54 6 0.09 mM in its ab-
sence) is not as clear-cut as in the case for wild-type FH. Thus,
PspCN binding reveals a difference between wild-type FH and
aHUS-linked FH(D1119G) that was not evident from SPR-based
C3b/C3d-binding studies performed without PspCN. All these
results reaffirm our hypothesis that PspCN is able to disinter the
occluded C-terminal C3b(TED)/C3d–binding site of wild-type FH.
In agreement with the aforementioned retention by full-length
FH(D1119G) of near–wild-type C3b-binding affinity, this muta-
tion did not affect C3bBb DAA (in the absence of PspCN and on
the foreign surface of the SPR chip) (Fig. 7C). Importantly, PspCN
induced only a small improvement in the DAA of FH(D1119G),
contrasting with the 5-fold improvement induced by PspCN in the
case of wild-type FH. This is a strong further endorsement of our
model in which the PspCN-induced improvement of DAA arises
from exposure of a non-disrupted C-terminal C3b/C3d-binding site.
We also investigated whether the aHUS-linked D1119G sub-
stitution perturbs the regulatory activity of FH on a surrogate host-
cell surface, as opposed to the foreign surface of an SPR chip. In
control assays, addition of wild-type FH to FHDNHS did not afford
much protection to rabbit erythrocyte surfaces that lack human-
like sialic acids (Fig. 10A). Alternatively, and concordant with
classical studies (50), sheep erythrocytes, which are rich in human-
like sialic acids, were protected by FH from complement-mediated
hemolysis (Fig. 10B). Crucially, FH(D1119G) protected neither
rabbit nor sheep erythrocytes. Thus, despite FH (wild-type)
binding to immobilized C3b, and decaying C3bBb no better than
FH(D1119G) on the “foreign” surface of a SPR chip, the wild-type
protein functions far better than the mutant on a surrogate host-cell
surface. This is in agreement with our hypothesis that FH binding to
C3b-bearing self-surfaces (but not foreign ones such as the SPR chip
surface) induces exposure of the C-terminal C3b(TED)-binding site
of wild-type FH that is missing in FH(D1119G).
(D39)PspCN can rescue complement-regulation deficiency
The PspCN:FH(wild-type) complex failed to fully protect rabbit
erythrocytes, used herein as surrogate foreign cells (Fig. 10A). This
is despite the enhanced C3b/C3d-binding and decay-accelerating
activity of the complex that was detected using SPR. An addi-
tional requirement for protection of bacteria is likely to be
localization of PspC on the bacterial surface (via the choline-
binding domain that is absent from PspCN) (see model in Fig. 11).
We partially recreated the scenario of a heterozygous individual
with the FH(D1119G) mutation by performing hemolysis assays
using a 1:1 mixture of wild-type FH and FH(D1119G). In our assay,
this mixture did not completely protect (human-like) sheep eryth-
rocytes from complement-mediated lysis (see FH+FH(D1119G) in
Fig. 10B). When PspCN was also included with the FH/FH(D119G)
mixture, no hemolysis could be detected. Moreover, soluble
(D39)PspCN boosted the ability of FH(D1119G) (in the absence
of wild-type FH) to protect (human-like) sheep erythrocytes
from complement-mediated lysis (Fig. 10B). This ability of PspCN
to partially rescue the regulatory activity of FH(D1119G) could
reflect the residual C3d binding of the mutated C terminus that
might also explain the small enhancements of C3b binding and
DAA induced in FH(D1119G) by PspCN.
Finally, we modeled PNH, wherein a somatic mutation results in
erythrocytes that lack the GPI-linked complement regulators, decay-
accelerating factor (CD55) and CD59 (that inhibits formation of the
membrane-attack complex, see Fig. 1A). The absence of these
regulators is linked to complement-mediated lysis of erythrocytes
in these patients. FH and FH-inspired candidate therapeutics
protect erythrocytes from PNH patients (25), as well as erythro-
cytes that have been stripped of GPI-linked proteins and rendered
“PNH-like” by treatment with 2-aminoethylisothiouronium bro-
mide (39). We demonstrated (Fig. 10C, 10D) dose-dependent
protection of PNH-like erythrocytes by (D39)PspCN acting in
partnership with FH.
Discussion
Building on previous work by others (31, 44), we showed that
recombinant N-terminal segments of both S. pneumoniae D39
PspC and Tigr4 PspC, sharing 50% sequence similarity, form
exceptionally stable complexes with FH. Resolving ambiguities in
past literature (44, 45, 47), we showed that (D39)PspCN binds
exclusively within CCPs 8–10 of FH. This agrees with a recent
report that a recombinant fragment (Tigr4)PspC68–148 [somewhat
smaller than our recombinant fragment (Tigr4)PspC37–179] binds
mainly to CCP 9 (48) (see below). (D39)PspCN undergoes folding
upon binding, whereas free (Tigr4)PspC68–148 exists as a three-
helical bundle. Strikingly, both the D39 and Tigr4 proteins bind
full-length FH two orders of magnitude more tightly than they
bind to any fragments of FH. This strongly implicates FH modules
other than the directly interacting ones in stabilization of the
complex with full-length protein. Attachment by central modules
to PspC likely induces formation of conformers that are not
readily kinetically available to free FH.
The recently reported crystal structure (PDB_ID = 4k12)
of Tigr4 PspC68–148 bound to FH 9 (48) reveals that 4 of 10
critical interface residues in this complex are not conserved in
(D39)PspCN (see Fig. 8A). Missing residues include TigR Tyr90,
FIGURE 11. Model for functional enhancement of FH by self-surface
markers and PspCN. Ovals represent CCPs; selected cross-links are shown
(see Fig. 5B). Circulating FH (center panels) adopts extended confor-
mations (from band s1 in Fig. 5A), not conducive to cross-links between
non-neighboring CCPs. Also adopted are more compact conformations
that are captured by cross-linking (from band s2 in Fig. 5A). We cannot tell
which of these prevail under physiological conditions. PspCN stabilizes
FH conformers that resemble the bent-back ones in s2 but that produce
different cross-linking patterns. The PspCN-stabilized FH conformers
(bottom left) bind better to C3b and C3d. Rearrangements of CCPs 7 and
20 probably contribute to functional enhancement, as this is where most
differences in cross-linking occur. These two CCPs also bind to GAGs and
sialic acid and to numerous other bacterial proteins. This suggests that
engagement with these markers of self-surfaces may induce a functionally
enhanced conformation of FH (bottom right) similar to the one captured by
cross-linking in band s4 of Fig. 5A.
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the “key inserted into a lock” of hydrophobic side chains within FH 9,
“latched” by an H-bond to the FH 9 backbone. Clearly, D39 PspC
and Tigr4 PspC must interact with different side chains within CCPs
8–10 of FH. Despite this, both have the same remarkable FH-
anchoring and function-enhancing capabilities. This supports our
theory that these bacterial proteins exploit an inherent propensity
of the FH molecule to switch to its enhanced conformation.
Cross-linking suggests (D39)PspCN increases FH dimerization.
No dimers could be detected by analytical ultracentrifugation
or multiple-angle light scattering. Nonetheless, PspCN-facilitated
conformational rearrangements could expose previously buried FH
regions that then favor self-association. Soluble GAG surrogates,
such as heparin, reportedly cause soluble FH to oligomerize (51).
Thus, in solution, both GAG:FH and PspCN:FH complexes may
self-associate, albeit weakly, via newly exposed interaction sites
(see Supplemental Table I). Whether this happens on surfaces is
unproven.
FH interacts well with C3b (KD of ∼500 nM) immobilized on an
SPR chip but poorly with C3d (i.e., the TED of C3b) in the same
context, as was also reported previously (25, 52). However, FH
19–20 (lacking CCPs 1–18) bound well to both C3b and C3d (KD
of ∼2 mM) (49). Clearly the FH C terminus is not fully competent
for binding C3d on this “foreign” (and therefore complement-
activating) chip surface. This binding site remains unavailable or
underutilized when FH interacts with similarly immobilized C3b,
explaining our critical observation that FH(D1119G) and wild-
type FH bind C3b equally well, despite partial disruption of the
TED/C3d-binding site in FH(D1119G) (49).
In contrast, the binding site for TED/C3d is fully available in
wild-type FH complexes with (D39)PspCN and (Tigr4)PspC37–179.
This is the simplest explanation for the massively enhanced
binding to surface-immobilized C3d of these complexes compared
with intact FH. Indeed (D39)PspCN:FH and (Tigr4)PspC37–179:FH
both bind C3d on the SPR chip just as well as does FH 19–20.
Simultaneous binding to C3b by both CCPs 1–4 and CCPs 19 and
20 of PspCN-bound FH explains its 2-fold higher affinity (than FH
alone) for C3b. This modest affinity difference could be critical for
survival of the bacterium in the host. Together with the marked
improvement in DAA, it could maintain levels of bacterial
surface-tethered C3b molecules below the threshold for run-away
activation via the positive-feedback amplification loop. This
would explain the improved hemolysis prevention properties of
soluble PspCN-bound FH (Fig. 10). The capacity of PspCN to
restore hemolysis protection in FHDNHS supplemented with a 1:1
mixture of wild-type FH and FH(D1119G) hints at therapeutic
potential as does the enhancement by PspCN of FH-mediated
protection of PNH-like erythrocytes that lack decay-accelerating
factor and CD59.
Most (11 of 15) of the differences in BS3–cross-linked peptides
found between FH before and after PspCN binding involve CCPs
7 and/or 20. Many bacterial FH-binding proteins (unlike PspC)
bind to both CCPs 7 and 20, potentially bringing them together.
This seems unlikely to be coincidental. It suggests other bacterial
complement-evasion proteins induce a broadly similar activated
FH conformation, albeit via a different mode of FH engagement.
Moreover, polyanionic self-surface markers also bind both CCPs 7
and 20 (16) (Fig. 11) as do oxidation-specific epitopes used for
recruiting FH to damaged cells (53). An intriguing possibility is
therefore that markers on self-surfaces also stabilize this, or
broadly similar, functionally enhanced conformations of FH, that
is, conformations characterized by an exposed TED/C3d-binding
site.
In conclusion, our evidence suggests that latent FH circulates
with some of its C3b-binding capabilities effectively locked away,
restricting its ability to regulate C3b amplification in fluid phase or
when passively captured by bacteria. FH also exists in a functionally
enhanced form, with both C3b-binding sites fully competent,
allowing binding to C3d and avid binding to C3b or (presumably)
C3bBb (Fig. 11). Tigr4 and D39 PspC both exploit the potential
existence of this functionally enhanced conformation and probably
other bacterial FH-binding proteins do as well. That bacteria are
able to induce a functionally enhanced conformation of FH suggests
self-surfaces do likewise. Thus, PspCN has likely revealed the
molecular basis of self versus non-self discrimination by the key
soluble regulator of the complement system.
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